🕵️ Entera BIO Ltd. ($ENTX)
SEC insider & ownership activity, last 12 months · CIK 1638097 · every row links its SEC filing
Over the last 12 months insiders bought $141K with no open-market selling against it. Geno J. Germano bought $56K in discretionary trades (Feb–Mar). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
5 buyers, $141K (8 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Geno J. Germano | 2 | $56K | 0 | – | Mar 9, 2026 |
| Ellis Sean | 2 | $35K | 0 | – | Mar 5, 2026 |
| Toledano Miranda Jayne | 1 | $20K | 0 | – | Dec 29, 2025 |
| Steven D. Rubin | 2 | $19K | 0 | – | Feb 12, 2026 |
| Taitel Haya | 1 | $11K | 0 | – | Feb 10, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| BVF Partners L P/IL | 10.0% | 13D | Jul 28, 2026 | filing ↗ | |
| BVF INC/IL | 10.0% | 13D | Jul 28, 2026 | filing ↗ | |
| Mark N. Lampert | 10.0% | 13D | Jul 28, 2026 | filing ↗ | |
| BVF GP Holdings LLC | 9.2% | 13D | Jul 28, 2026 | filing ↗ | |
| OPKO Health, Inc. | 8.1% | 13G | Apr 2, 2025 | filing ↗ | |
| TCG Crossover GP III, LLC | 7.1% | 13G | Aug 4, 2026 | filing ↗ | |
| TCG Crossover Fund III, L.P. | 7.1% | 13G | Aug 4, 2026 | filing ↗ | |
| Chen Yu | 7.1% | 13G | Aug 4, 2026 | filing ↗ | |
| VIVO Opportunity, LLC | 6.9% | 13G | Aug 4, 2026 | filing ↗ | |
| Biotechnology Value Fund L P | 5.3% | 13D | Jul 28, 2026 | filing ↗ | |
| BVF I GP LLC | 5.3% | 13D | Jul 28, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Aug 18, 2026 | filing ↗ |
| Other events (8.01) | Aug 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 18, 2026 | filing ↗ |
| Earnings (2.02) | Aug 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Aug 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 7, 2026 | filing ↗ |
| Material agreement (1.01) | Jul 26, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jul 26, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 26, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jul 14, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jul 14, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Earnings (2.02) | May 8, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | May 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 8, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 1, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Apr 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 1, 2026 | filing ↗ |
| Earnings (2.02) | Mar 27, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 27, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 27, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing ↗ |
| Officer/director changes (5.02) | Feb 4, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 4, 2026 | filing ↗ |
| Material agreement (1.01) | Jan 29, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jan 29, 2026 | filing ↗ |